The decrease in CD8% T cells in the spleen following treatment with 11B12-1 and 12F1-1 may be a consequence of changes in immune checkpoint signalling resulting in CD8 T cell activation and infiltration of cells away from the spleen to the tumour site. The gene discussed is CD8A; the disease is neoplasm.